Enamel Matrix Derivative in the Reconstructive Surgical Therapy of Peri‐Implantitis: A Randomized Clinical Trial
Journal of Periodontal Research · 2026
DOI: 10.1111/jre.13396 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Periodontal Research, 2026. Verfasst von Erik Regidor und 6 weiteren Autor:innen. Beteiligte Einrichtung: Periodontal and Peri-Implant Related Diseases and Therapies, Arrow Development SL, Bilbao, Spain. Hauptthemen laut MEDLINE: Peri-Implantitis, Dental Enamel Proteins, Plastic Surgery Procedures. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: Straumann Research Grant, Institut Straumann AG (Peter Merian-Weg 12, 4002 Basel, Switzerland), Arrow Development SL. (Mazarredo 22, 11B 48009 Bilbao Spain).
Abstract (Originalsprache)
Aims
To evaluate the adjunctive effect of enamel matrix derivative (EMD) in the reconstructive surgical therapy of peri‐implantitis.
Methods
Forty subjects (44 implants) affected by peri‐implantitis (PPD ≥ 5 mm, positive BOP/SOP, intraosseous defect with a depth of ≥ 3 mm and width of ≤ 4 mm) were randomly allocated to one of two surgical protocols: control (access flap + bone graft + resorbable membrane) or test (access flap + bone graft + resorbable membrane + EMD). Clinical outcomes (PPD, BOP, SOP, buccal REC, and buccal KM) were assessed at baseline, 6 and 12 months after surgery. Radiographic marginal bone levels (MBL) and patient‐reported outcomes (PROs) were recorded at baseline and at 12 months. Post‐operative complications and Early Healing Index (EHI) scores were recorded at 2 weeks. The primary outcome was PPD change. Two composite outcomes (CO) were assessed: CO1 was defined as “implant not lost, PPD ≤ 5 mm, REC ≤ 1 mm and complete absence of BOP/SOP”; CO2 defined as CO1 but allowing for 1 site with BOP.
Results
Four patients (four implants) were lost to follow‐up. At 12 months, no implants were lost, 73% of implants presented with PPD ≤ 5 mm (control: 65.2%; test: 81.0%; p = 0.316) and PPD reduction amounted to 4.0 ± 1.7 and 4.3 ± 2.4 mm in control and test groups, respectively ( p = 0.105). No significant differences in terms of clinical, radiographic, composite and PROs were observed between groups. No significant differences in EHI scores were found at 2 weeks between groups.
Conclusion
This study failed to demonstrate any benefit of the adjunctive use of EMD in the reconstructive surgical therapy of peri‐implantitis. Trial Registration: ISRCTN18159776 ( https://doi.org/10.1186/ISRCTN18159776 )
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Periodontal and Peri-Implant Related Diseases and Therapies, Arrow Development SL, Bilbao, Spain.
- Department of Periodontology, Institute of Odontology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
ORCID-Profile: Erik Regidor
Förderung
- Straumann Research Grant, Institut Straumann AG (Peter Merian-Weg 12, 4002 Basel, Switzerland)
- Arrow Development SL. (Mazarredo 22, 11B 48009 Bilbao Spain)
Zitieren
APA
Regidor, E., Dionigi, C., Ghoraishi, M., Salazar, J., Trullenque-Eriksson, A., Derks, J., & Ortiz-Vigón, A. (2026). Enamel Matrix Derivative in the Reconstructive Surgical Therapy of Peri‐Implantitis: A Randomized Clinical Trial. Journal of Periodontal Research. https://doi.org/10.1111/jre.13396
Vancouver
Regidor E, Dionigi C, Ghoraishi M, Salazar J, Trullenque-Eriksson A, Derks J, et al. Enamel Matrix Derivative in the Reconstructive Surgical Therapy of Peri‐Implantitis: A Randomized Clinical Trial. Journal of Periodontal Research. 2026. doi:10.1111/jre.13396
BibTeX
@article{Regidor2026,
author = {Regidor, Erik and Dionigi, Carlotta and Ghoraishi, Martina and Salazar, Jon and Trullenque-Eriksson, Anna and Derks, Jan and Ortiz-Vigón, Alberto},
title = {Enamel Matrix Derivative in the Reconstructive Surgical Therapy of Peri‐Implantitis: A Randomized Clinical Trial},
journal = {Journal of Periodontal Research},
year = {2026},
doi = {10.1111/jre.13396}
}
EUVIMED